Fig. 5From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR geneRepression of EGFR is an obligatory intermediate step for KLF4 to inhibit aggressive breast cancer phenotypes. MCF10A cells were transfected with siNS, siKLF4, siEGFR, or siKLF4+siEGFR, and western blots were performed to confirm a KLF4 and b EGFR silencing. Cells were then allowed to c migrate for 6 h or d invade for 16 h before they were stained and counted. e MCF10A cells were transfected with siNS, siKLF4, siEGFR, or siKLF4+siEGFR, and cell number was counted at days 3–5 using trypan blue exclusion assay, *p < 0.05. f Apoptotic MCF10A cells were assessed using Hoechst stain 3 days after transfection. g EdU staining was used to quantify the number of proliferating MCF10A cells 3 days post-transfection. For all data, relative values were normalized versus the control, and error bars represent the standard deviation. Bars with distinct letters above them are significantly different from one another (p < 0.05). Experiments were performed three independent times in triplicateBack to article page